The optimal strategy of multimodality therapies for resectable gastric cancer: evidence from a network meta-analysis

Conclusions: Our study showed no significant survival advantage for neoadjuvant CRT, though the highest probability of being the best treatment was observed. Further clinical trials are essential to determine the value of neoadjuvant CRT, especially in D2 lymphadenectomy subgroup.

Source: Journal of Cancer - June 13, 2019 Category: Cancer & Oncology Authors: Songcheng Yin, Pengliang Wang, Xiaoyu Xu, Yuen Tan, Jinyu Huang, Huimian Xu Tags: Research Paper Source Type: research